Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 5/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6321285 | 0.84 | LMNA (0.51) | ALDH1A1POLBMAPTRAB9ANPC1 | |
| SCHEMBL29673912 | 0.82 | ALDH1A1 (0.57) | ALDH1A1POLBMAPTRAB9ANPC1 | |
| SCHEMBL29673906 | 0.82 | ALDH1A1 (0.57) | ALDH1A1POLBMAPTRAB9ANPC1 | |
| SCHEMBL3562174 | 0.81 | ALDH1A1 (0.56) | ALDH1A1POLBRAB9ANPC1LMNA | |
| SCHEMBL3569456 | 0.81 | ALDH1A1 (0.56) | ALDH1A1POLBRAB9ANPC1LMNA | |
| SCHEMBL3559805 | 0.80 | ALDH1A1 (0.55) | ALDH1A1POLBRAB9ANPC1LMNA | |
| SCHEMBL13037180 | 0.80 | ALDH1A1 (0.55) | ALDH1A1POLBRAB9ANPC1LMNA | |
| SCHEMBL6319987 | 0.77 | KMT2A (0.70) | ALDH1A1POLBLMNAKMT2AMEN1 | |
| SCHEMBL11744707 | 0.76 | HSD17B10 (0.70) | ALDH1A1POLBMAPTRAB9ANPC1 | |
| SCHEMBL179087 | 0.76 | LMNA (0.60) | ALDH1A1MAPTRAB9ANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908931-B2 | Tetrahydroisoquinoline derivatives as melatonin MT2 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040235891-A1 | Tetrahydroisoquinoline derivatives as melatonin MT2 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235891-A1 | Tetrahydroisoquinoline derivatives as melatonin MT2 antagonists | MTNR1A, MTNR1B, PER2 | ALDH1A1 1598/4885POLB 2664/4885MAPT 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.